Chemerin-9 (149-157) (TFA)|西域试剂

Chemerin-9 (149-157) (TFA),99.64%

产品编号：Bellancom-P1844A| 分子式：C₅₆H₆₇F₃N₁₀O₁₅| 分子量：1177.18

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1844A	￥1200.00	杭州北京（现货）
Bellancom-P1844A	￥2500.00	杭州北京（现货）
Bellancom-P1844A	￥4500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Chemerin-9 (149-157) (TFA)

产品介绍

Chemerin-9 (149-157) TFA 是趋化因子样受体1 (CMKLR1) 的有效激动剂。Chemerin-9 (149-157) TFA 具有抗炎活性。Chemerin-9 (149-157) TFA 刺激 Akt 和 ERK 的磷酸化以及活性氧的产生。Chemerin-9 (149-157) TFA 改善 Aβ_1-42 诱导的记忆障碍。Chemerin-9 (149-157) TFA 调节免疫反应、脂肪细胞分化和糖代谢。

生物活性

Chemerin-9 (149-157) TFA is a potent agonist of chemokine-like receptor 1 (CMKLR1) . Chemerin-9 (149-157) TFA has anti-inflammatory activity. Chemerin-9 (149-157) TFA stimulates phosphorylation of Akt and ERK as well as ROS production. Chemerin-9 (149-157) TFA ameliorates Aβ_1-42-induced memory impairmen. Chemerin-9 (149-157) TFA regulates immune responses, adipocyte differentiation, and glucose metabolism^[4].

体外研究

Chemerin-9 (149-157) TFA (0.1 nM; 24 h; cardiac fibroblasts) stimulates migration in cardiac fibroblasts and stimulates phosphorylation of Akt and ERK as well as ROS production^[4].

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[4]

Cell Line:	Cardiac fibroblasts
Concentration:	0.1 nM
Incubation Time:	24 hours
Result:	Stimulated phosphorylation of Akt and ERK.

体内研究
(In Vivo)

Chemerin-9 (149-157) TFA (0.2 mg/kg; i.p.; daily, for 42 days) alleviates glucose intolerance and IR in PDM mice.
Chemerin-9 (149-157) TFA (7.7 μg /kg; i.h.; daily, for 28 days) has anti-inflammatory and anti-angiogenic effects in ApoE^-/- mice and protects the abdominal aorta from MMP damage.
Chemerin-9 (149-157) TFA (8 μg/kg; ICV; daily; for 14 d; male Kunming mice) ameliorates Aβ_1-42-induced memory impairment.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PDM mice
Dosage:	0.2 mg/kg
Administration:	Intraperitoneal injection; daily, for 42 days
Result:	Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Suppressed the enlargement of abdominal aorta and reversed the SMC loss.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1.

Animal Model:	Male Kunming mice
Dosage:	8 μg/kg
Administration:	Intracerebroventrical injection; daily; for 14 days
Result:	Increased in the levels of pro-inﬂammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PDM mice
Dosage:	0.2 mg/kg
Administration:	Intraperitoneal injection; daily, for 42 days
Result:	Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Suppressed the enlargement of abdominal aorta and reversed the SMC loss.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1.

Animal Model:	Male Kunming mice
Dosage:	8 μg/kg
Administration:	Intracerebroventrical injection; daily; for 14 days
Result:	Increased in the levels of pro-inﬂammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	PDM mice
Dosage:	0.2 mg/kg
Administration:	Intraperitoneal injection; daily, for 42 days
Result:	Increased expression of chemerin, GLUT2, and PDX1, which led to the alleviation of glucose intolerance and IR in PDM model mice.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Suppressed the enlargement of abdominal aorta and reversed the SMC loss.

Animal Model:	ApoE^-/- mice
Dosage:	7.7 μg /kg
Administration:	Subcutaneous injection; daily, for 28 days
Result:	Down-regulated MMP2 and MMP-9 expression and decreased the levels of chemerin and CMKLR1.

Animal Model:	Male Kunming mice
Dosage:	8 μg/kg
Administration:	Intracerebroventrical injection; daily; for 14 days
Result:	Increased in the levels of pro-inﬂammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor (TNF-α) and interleukin-6 (IL-6) in the hippocampus.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (84.95 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.8495 mL	4.2474 mL	8.4949 mL
5 mM	0.1699 mL	0.8495 mL	1.6990 mL
10 mM	0.0849 mL	0.4247 mL	0.8495 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Sealed storage, away from moisture